Scarica l'app Stockscreener
9.90
7.03%
0.65
Pre-mercato:
9.75
-0.15
-1.52%
Precedente Chiudi:
$9.25
Aprire:
$9.45
Volume 24 ore:
2.05M
Relative Volume:
2.80
Capitalizzazione di mercato:
$539.95M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+6.80%
1M Prestazione:
-31.72%
6M Prestazione:
-50.52%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$9.303
$10.32
Intervallo di 1 settimana:
$8.94
$10.32
Portata 52W:
$7.80
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Nome
Bicara Therapeutics Inc
Settore
Industria
Telefono
617-785-8308
Indirizzo
245 MAIN STREET, CAMBRIDGE
Confronta BCAX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
9.90 | 544.27M | 0 | 0 | 0 | 0.00 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-23 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | Iniziato | Wells Fargo | Underweight |
| 2025-02-06 | Iniziato | Wedbush | Outperform |
| 2024-12-06 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-05 | Iniziato | Rodman & Renshaw | Buy |
| 2024-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-08 | Iniziato | Morgan Stanley | Overweight |
| 2024-10-08 | Iniziato | Stifel | Buy |
| 2024-10-08 | Iniziato | TD Cowen | Buy |
Mostra tutto
Bicara Therapeutics Inc Borsa (BCAX) Ultime notizie
Stifel reiterates Buy rating on Bicara Therapeutics stock - Investing.com Australia
Cantor Fitzgerald reiterates overweight rating on Bicara Therapeutics stock By Investing.com - Investing.com Nigeria
Stifel reiterates Buy rating on Bicara Therapeutics stock By Investing.com - Investing.com India
Bicara Responds to Rival Merus With Early Survival Data at #ASCO25 - BioSpace
Cantor Fitzgerald reiterates overweight rating on Bicara Therapeutics stock - Investing.com
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara presents promising early-stage data in head and neck cancers - The Business Journals
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus ... - Enidnews.com
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 - GlobeNewswire
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 - GlobeNewswire Inc.
Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients - MSN
Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update - Insider Monkey
Bicara Therapeutics Inc. (NASDAQ:BCAX) Shares Bought by Millennium Management LLC - Defense World
PIZZA PIZZA ROYALTY CORP. ANNOUNCES MAY DIVIDEND and TIMING OF ANNUAL GENERAL MEETING - The Globe and Mail
159,043 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Purchased by Northern Trust Corp - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Earns “Outperform” Rating from Wedbush - Defense World
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Raised to Equal Weight at Wells Fargo & Company - Defense World
Stifel maintains Bicara stock Buy rating, $48 target post-ASCO - Investing.com Australia
Stifel maintains Bicara stock Buy rating, $48 target post-ASCO By Investing.com - Investing.com Canada
112,476 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Acquired by Deutsche Bank AG - Defense World
Bicara falls after early-stage trial data for head and neck cancer therapy - MSN
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics - MSN
Bicara Therapeutics (NASDAQ:BCAX) Stock Rating Lowered by Wall Street Zen - Defense World
Wells Fargo Upgrades Bicara Therapeutics (BCAX) - Nasdaq
Bicara Therapeutics Shares Sink Over 43% On Mixed Phase 1/1b Trial Results: What's Going On? - Benzinga
Bicara: Stock Decline On FICERA Abstract Release Creates Buying Opportunity (NASDAQ:BCAX) - Seeking Alpha
Biotech Soars On 'Unprecedented' Results, Slamming Its Rival - Investor's Business Daily
Wells Fargo Upgrades Bicara Therapeutics to Equal Weight From Underweight, $8 Price Target - marketscreener.com
Bicara Therapeutics upgraded to Equal Weight from Underweight at Wells Fargo - TipRanks
Wells upgrades Bicara to Equal Weight with thesis played out - TipRanks
Gold Gains Over 1%; Ross Stores Shares Dip After Pulling Fiscal 2026 Outlook - Benzinga
Bicara stock falls after data for lead drug (BCAX:NASDAQ) - Seeking Alpha
Nasdaq Down Over 1%; Workday Shares Tumble After Q1 Results - Benzinga
Why Is Bicara Therapeutics Stock (BCAX) Down 30% Today? - TipRanks
Ross Stores, Deckers Outdoor, Xerox Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa in HPV-Negative HNSCC Drives Buy Rating - TipRanks
Promising Efficacy and Survival Data Drive Buy Rating for Bicara Therapeutics - TipRanks
Bicara Therapeutics to present head and neck cancer study data - Investing.com Australia
ASCO25 abstract roundup: Roche's Itovebi cuts risk of death; Merus' bispecific impresses in HNSCC, while Bicara's disappoints - FirstWord Pharma
Bicara Therapeutics publishes updated data from Phase 1/1b trial of Ficerafusp - TipRanks
Bicara Therapeutics to present head and neck cancer study data By Investing.com - Investing.com Nigeria
Bicara Therapeutics stock tumbles on clinical trial data - Investing.com Australia
Bicara Therapeutics stock tumbles on clinical trial data By Investing.com - Investing.com Nigeria
Bicara Therapeutics Inc. Announces Updated Interim Data from Phase 1/1b Trial of Ficerafusp Alfa in Head and Neck Cancer Ahead of ASCO Presentation - Nasdaq
Bicara Therapeutics Announces Publication of an Abstract - GlobeNewswire
Micro-Cap Tech Firm Reports Triple-Digit Revenue Growth as Shares Climb - The Globe and Mail
Research Analysts Set Expectations for BCAX FY2026 Earnings - Defense World
TD Cowen reiterates Buy on Bicara Therapeutics stock - Investing.com Australia
TD Cowen reiterates Buy on Bicara Therapeutics stock By Investing.com - Investing.com Nigeria
FY2025 EPS Forecast for Bicara Therapeutics Cut by Analyst - Defense World
Bicara Therapeutics Inc Azioni (BCAX) Dati Finanziari
Non sono disponibili dati finanziari per Bicara Therapeutics Inc (BCAX). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
6.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):